BioSpace News Archive

MedAustron, RaySearch’s first customer for carbon ion therapy treatment planning in RayStation back in 2012, has now decided to replace existing systems and only use RaySearch software exclusively.

Prominence is honored to be named, for the seventh year in a row, as one of the best Chicago companies and organizations to work for across industries.

Hamamatsu Photonics will construct a new factory building at the Shingai Factory (Shingai-cho, Minami-ku, Hamamatsu City, Japan) to cope with increasing sales demand for opto-semiconductors, X-ray image sensors and X-ray flat panel sensors. The new factory building will be completed in August 2020.

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the upsizing and pricing of the underwritten public secondary offering previously announced by Chi-Med on June 27, 2019.

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that Hutchison Healthcare Holdings Limited (“HHHL”), the largest shareholder of Chi-Med and a subsidiary of CK Hutchison Holdings Limited (SEHK: 1), intends to offer 8,500,000 American Depositary Shares (“ADSs”), each representing five ordinary shares (“Ordinary Shares”), par value US$0.10 each of Chi-Med (“Offering”).

This week, 13-year-old Hope Dees of Land O’ Lakes, FL joined more than 50 other pediatric patients from across the nation on Capitol Hill to meet with their members of Congress to speak out on behalf of children with complex medical conditions.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed the previously announced sale of its Anatomical Pathology business to PHC Holdings Corporation, a leading global healthcare company providing innovative solutions, for approximately $1.14 billion in cash.

Ernst & Young (EY) honored Nephron Pharmaceuticals President and CEO Lou Kennedy as Health Care Entrepreneur of the Year for the Southeast on Thursday during a gala at the Coca-Cola Roxy in Atlanta.

PHC Holdings Corporation (headquarters: Tokyo, Japan, hereafter PHCHD) today announced the completion of its acquisition of Anatomical Pathology business of Thermo Fisher Scientific Inc. (NYSE: TMO, hereafter Thermo Fisher) for approximately US$1.14 billion.

iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, is pleased to announce that its U.S. subsidiary has closed the previously announced acquisition of CBD For Life, a top-ranked, national CBD brand in the U.S.